Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine ( AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

被引：50
|
作者：
Gojo, Ivana [1 ]
Stuart, Robert K. [2 ]
Webster, Jonathan [1 ]
Blackford, Amanda [3 ]
Varela, Juan Carlos [4 ]
Morrow, Jillian [1 ]
DeZern, Amy E. [1 ]
Foster, Matthew C. [5 ]
Levis, Mark J. [1 ]
Coombs, Catherine C. [5 ]
Prince, Gabrielle T. [6 ]
Smith, B. Douglas [7 ]
Van Deventer, Hendrik W. [5 ]
Jamieson, Katarzyna [5 ]
Varadhan, Ravi [1 ]
Vincent, Benjamin G. [5 ]
Serody, Jonathan S. [5 ]
Luznik, Leo [1 ]
Zeidner, Joshua F. [5 ]
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Florida Hosp, Blood & Marrow Transplant Ctr, Orlando, FL USA
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins Med Inst, Baltimore, MD USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127345
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
832
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Konopleva, Marina
    Maiti, Abhishek
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Loghavi, Sanam
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Golez, Michelle
    Pierce, Sherry A.
    Nogueras Gonzalez, Graciela M.
    Ning, Jing
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2021, 138
  • [2] Phase II trial of arsenic trioxide (ATO) in relapsed and refractory acute myeloid leukemia (AML), secondary leukemia, and/or newly diagnosed patients >65 years old.
    Parmar, S
    Rundhaugen, LM
    Boehlke, LL
    Riley, MB
    Nabhan, C
    Raji, A
    Tallman, MS
    BLOOD, 2002, 100 (11) : 337A - 338A
  • [3] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Senapati, Jayastu
    Maiti, Abhishek
    Loghavi, Sanam
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Pierce, Sherry A.
    Gonzalez, Graciela M. Nogueras
    Ning, Jing
    Issa, Ghayas C.
    Andreeff, Michael
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2022, 140
  • [4] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [5] A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
    Murthy, Guru Subramanian Guru
    Kaufmann, Scott H.
    Szabo, Aniko
    Harrington, Alexandra M.
    Michaelis, Laura C.
    Abedin, Sameem
    Carlson, Karen
    Runaas, Lyndsey
    Longo, Walter L.
    Hinman, Alexander
    Maldonado-Schmidt, Sonia
    Thomas, Althea
    Baim, Arielle
    Litzow, Mark R.
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [6] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kim, Kunhwa
    Kantarjian, Hagop
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas J.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Chien, Kelly S.
    Daver, Naval
    Pemmaraju, Naveen
    Jain, Nitin
    Adewale, Lade
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Verstovsek, Srdan
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [7] Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission.
    Bazinet, Alexandre
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Bose, Prithviraj
    Jabbour, Elias
    Valero, Yesid Alvarado
    Chien, Kelly Sharon
    Pemmaraju, Naveen
    Takahashi, Koichi
    Short, Nicholas James
    Daver, Naval Guastad
    Issa, Ghayas C.
    Jain, Nitin
    Bull-Linderman, Debra
    Dinardo, Courtney Denton
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19018 - E19018
  • [8] A phase I study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)
    Yee, Karen W.
    Brandwein, Joseph
    Minden, Mark D.
    Sanfelice, Deborah
    Chow, Sue
    Hedley, David W.
    Schimmer, Aaron D.
    Schuh, Andre C.
    Gupta, Vikas
    Sidor, Carolyn F.
    Arnott, Jamie
    Fletcher, Graham
    Bray, Mark
    Chen, Hsiao-Wei Tina
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [9] AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN ELDERLY PATIENTS (≥75 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML) IN THE AZA-AML-001 STUDY
    Seymour, J. F.
    Buckstein, R.
    Santini, V.
    Doehner, H.
    Stone, R. M.
    Minden, M. D.
    Kuo, C. Y.
    Ben-Yehuda, D.
    Bargay, J.
    Songer, S.
    Weaver, J.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2017, 55 : S67 - S68
  • [10] Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study
    Seymour, John F.
    Buckstein, Rena
    Santini, Valeria
    Doehner, Hartmut
    Stone, Richard M.
    Minden, Mark D.
    Kuo, Ching-Yuan
    Ben-Yehuda, Dina
    Bargay, Joan
    Songer, Stephen
    Weaver, Jerry
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2016, 128 (22)
12345